Interim Safety and Biomarker Data From upliFT‐D Trial of PBFT02 in FTD with GRN Mutations
Interim safety and biomarker data from the upliFT-D trial provides early evidence that PBFT02 has potential as a one-time therapy for FTD-GRN, thus supporting further clinical development.
Authors
- Wen‐Hai Chou (ORCID: https://orcid.org/0000-0002-7899-1129)
- Ni Yan (ORCID: https://orcid.org/0000-0002-7390-3804)
- Paul Ernest Schulz (ORCID: https://orcid.org/0000-0003-0676-002X)
- Carmela M. Tartaglia
- Simon Ducharme (ORCID: https://orcid.org/0000-0002-7309-1113)
- Tiffini Voss
- Leonel Tadao Takada
- Paulette Triglia
- Isabel Santana
- Sue Browne
- David J. Irwin
- Leonardo Cruz de Souza
Institutions
- Universidade Federal de Minas Gerais (BR)
- Montreal Neurological Institute and Hospital (CA)
- University of Toronto (CA)
- Hospitais da Universidade de Coimbra (PT)
- Pennsylvania Academy of Science (US)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- McGill University (CA)
- University of Pennsylvania (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103638
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00